Uncategorized

Can Revolution’s ‘miracle’ pancreatic cancer drug be topped? Immuneering, Actuate say yes

Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve on that result with increased tolerability—and more time for patients.

Can Revolution’s ‘miracle’ pancreatic cancer drug be topped? Immuneering, Actuate say yes Read More »

Scroll to Top